First Bangladeshi pharmaceutical company to launch pharmaceutical
products in the US
Dhaka, August 04, 2016: Beximco Pharmaceuticals
Limited ("BPL", "Beximco Pharma" or "Company";
AIM Symbol: BXP), the fast-growing manufacturer of generic pharmaceutical
products and active pharmaceutical ingredients, today announces it has commenced the export of Carvedilol, a prescription drug for treating
hypertension, to the US. This follows
the product’s approval from the US Food and Drug Administration (“US FDA”) in
November 2015 and is the first time a pharmaceutical product from Bangladesh has
been launched in the US.
To mark the delivery of the first
consignment on 4 August 2016, and to celebrate this milestone achievement for
Beximco Pharma, a brief ceremony was held in the presence of Finance Minister, Mr. Abul Maal Abdul Muhith MP, Health
and Family Welfare Minister, Mr.
Mohammed Nasim MP and the US Ambassador to Bangladesh Her Excellency Marcia Stephens Bloom
Bernicat. Senior officials from different ministries, including
the Export Promotion Bureau (EPB), the Federation of Bangladesh Chambers of
Commerce and Industry (FBCCI) and the Bangladesh Association of Pharmaceutical Industries
(BAPI) were also in attendance. Honourbale Ministers highly praised about
Beximco Pharma’s initiatives for taking Bangladeshi medicines to the world and
for making significant contribution to country’s remarkable progress in
healthcare. The US Ambassador hoped that with
the commencement of pharmaceutical export from Bangladesh, business and
cooperation between the two countries will continue to expand and reach new
heights in the coming days.
Earlier
in the day a brief plaque unveiling ceremony was held at the company’s factory
premises in Tongi by the
US Ambassador.
Commenting on the news, Beximco
Group Vice Chairman Mr. Salman F Rahman said, “Today is a significant milestone
for Beximco Pharma. As we deliver our first shipment of Carvedilol to the
US market, we begin a new era for the pharmaceutical industry in Bangladesh. We
believe our continued focus on building and strengthening the Group’s presence
in Western markets will cement Bangladesh’s position as a major exporting
country.”
Beximco Pharma Managing Director
Mr. Nazmul Hassan MP continued, “These initiatives
are in line with our aspirations to expand our reach by taking products to the
world. The US is the largest and most
lucrative pharmaceutical market in the world. As a leading exporter of
medicines, we always strive to capitalise on the generic drug opportunities in
the world market. We believe our
competitive products, especially with specialised and differentiated generic products,
will help strengthen our presence in the US and other advanced
markets.”
Beximco Pharma became the first
Bangladeshi pharmaceutical company audited and approved by the US FDA in June 2015.
Beximco Pharma is the largest
exporter of pharmaceuticals in Bangladesh, winning the country’s National
Export Trophy (Gold) a record five times, the highest national accolade for
export. The Company currently has a
global footprint in more than 50 countries and has been accredited by a number
of global regulatory authorities, including US FDA, AGES (EU), TGA Australia,
Health Canada, GCC and TFDA.
# Beximco Pharma, # Salman F Rahman